Checked
International Stem Cell Corp
OTC: ISCO · Pharmaceutical Preparations · San Diego, CA
- Revenue
- $9.1M
- +0.2% vs. prior year
- Net income
- -$418K
- -4.6% net margin
- Total assets
- $4.82M
- Diluted EPS
- -$0.05
Company details
As reported to the SEC
- SEC CIK
- 1355790
- Stock
- OTC: ISCO
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 9745 Businesspark Avenue, San Diego, CA 92131
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (760) 940-6383
- Employer ID (EIN)
- 20-4494098
- Last annual report
- 03/30/2026
- Last quarterly report
- 08/13/2026
Formerly: BTHC III INC. (until 01/19/2007)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $9.1M | $9.09M | $7.79M | $8.18M | $7.18M |
| Operating income | -$267K | -$68K | -$663K | -$183K | -$1.92M |
| Net income | -$418K | -$209K | -$131K | -$331K | -$899K |
| Diluted earnings per share | -$0.05 | -$0.03 | -$0.02 | -$0.04 | -$0.11 |
| Research and development | $684K | $657K | $511K | $492K | $695K |
| Total assets | $4.82M | $5.17M | $5.39M | $5.13M | $4.95M |
| Total liabilities | $4.58M | $4.8M | $5.28M | $5.36M | $5.23M |
| Shareholders' equity | -$4.06M | -$3.93M | -$4.19M | -$4.52M | -$4.59M |
| Cash and cash equivalents | $993K | $1.23M | $1.59M | $742K | $171K |
| Cash from operations | $8K | $13K | $929K | $332K | -$1.3M |
| Capital expenditures | $43K | $166K | $80K | $1K | $23K |
$7.13M
$7.18M
$8.18M
$7.79M
$9.09M
$9.1M
Recent filings
162 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KAcquisition or sale of assets | 09/08/2026 | 09/01/2026 |
| 10-QQuarterly report | 08/13/2026 | 06/30/2026 |
| DEF 14CSEC filing | 08/04/2026 | 08/04/2026 |
| PRE 14CSEC filing | 07/24/2026 | 07/24/2026 |
| 8-KMaterial agreement | 07/16/2026 | 07/10/2026 |
| 8-KShareholder vote results | 06/12/2026 | 06/11/2026 |
| 10-QQuarterly report | 05/14/2026 | 03/31/2026 |
| ARSAnnual report to shareholders | 04/29/2026 | 12/31/2025 |
| DEF 14AProxy statement | 04/29/2026 | 06/11/2026 |
| 10-KAnnual report | 03/30/2026 | 12/31/2025 |
| 8-KShareholder vote results | 11/18/2025 | 06/17/2025 |
| 10-QQuarterly report | 11/13/2025 | 09/30/2025 |
| 8-KMaterial agreement, New debt or obligation | 09/16/2025 | 09/15/2025 |
| 10-QQuarterly report | 08/14/2025 | 06/30/2025 |
| 10-QQuarterly report | 05/14/2025 | 03/31/2025 |
| ARSAnnual report to shareholders | 04/24/2025 | 12/31/2024 |
| DEF 14AProxy statement | 04/24/2025 | 06/17/2025 |
| 10-KAnnual report | 03/28/2025 | 12/31/2024 |
| 10-QQuarterly report | 11/13/2024 | 09/30/2024 |
| 8-KMaterial agreement, New debt or obligation | 09/17/2024 | 09/15/2024 |
5 insider ownership reports (Forms 3, 4, 5 and 144) were filed about International Stem Cell Corp in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is International Stem Cell Corp's CIK number?
- International Stem Cell Corp's SEC Central Index Key (CIK) is 1355790.
- What is International Stem Cell Corp's stock ticker?
- International Stem Cell Corp trades as OTC: ISCO.
- What was International Stem Cell Corp's revenue?
- International Stem Cell Corp reported revenue of $9.1M for the fiscal year ended Dec 31, 2025, +0.2% from the year before.
- When does International Stem Cell Corp's fiscal year end?
- International Stem Cell Corp's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is International Stem Cell Corp headquartered?
- International Stem Cell Corp's principal executive office on file with the SEC is in San Diego, CA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026